Safety and Immunogenicity Study in Young Adults the Meningococcal Serogroup C Vaccine Produced by Bio-Manguinhos

NCT01889836 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
60
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)